Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic intraperitoneal paclitaxel for resectable locally advanced gastric/GEJ adenocarcinoma
ChiCTR2600125234Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paclitaxel in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Ruijin Hospital. Primary endpoint: Event-free survival. Planned start May 2026; status: not yet recruiting.
02
Drugs
paclitaxel
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600125234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125234.